Telavant, A Roivant Company, Advances Inflammatory Bowel Disease Program With First Patient Dosed In Global Phase 2 Trial Of Novel Anti-TL1A Antibody RVT-3101 In Crohn's Disease
Portfolio Pulse from Happy Mohamed
Telavant, a Roivant company, has initiated a Phase 2 clinical trial of RVT-3101 for the treatment of moderate to severely active Crohn's disease. This follows Roivant's recent announcement of favorable results from a Phase 2b study of RVT-3101 in ulcerative colitis. The TAHOE study will evaluate the safety and efficacy of RVT-3101 in patients with Crohn's disease.
July 27, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roivant's subsidiary, Telavant, has initiated a Phase 2 trial of RVT-3101 for Crohn's disease. This follows positive results from a Phase 2b study in ulcerative colitis, suggesting potential for the drug's success.
The initiation of a Phase 2 trial for RVT-3101 in Crohn's disease indicates progress in Telavant's drug development program. The recent positive results from a Phase 2b study in ulcerative colitis suggest potential for the drug's efficacy, which could positively impact Roivant's stock in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100